Hqtor 400mg Tablet (hydroxychloroquine)

Description

Hqtor 400mg Tablet (hydroxychloroquine) — Complete Clinical and Patient Information Guide

Product Overview

Hqtor 400mg Tablet (hydroxychloroquine) contains Hydroxychloroquine Sulphate 400mg as its active pharmaceutical ingredient, belonging to the aminoquinoline antimalarial and disease-modifying anti-rheumatic drug (DMARD). It is clinically indicated for rheumatoid arthritis (DMARD — monotherapy or combination with methotrexate/sulfasalazine), systemic lupus erythematosus (SLE — reduces flares, organ damage, and mortality), lupus nephritis (adjunct), primary Sjögren’s syndrome, discoid lupus erythematosus, and malaria prophylaxis/treatment. This guide is prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines.

Hqtor 400mg provides hydroxychloroquine sulphate 400mg — a cornerstone antimalarial and DMARD with proven long-term benefit in SLE survival, RA disease control, and autoimmune disease management, requiring consistent use and annual ophthalmic monitoring.

Mechanism of Action

Hydroxychloroquine (HCQ) is an antimalarial drug with broad immunomodulatory and disease-modifying properties that have made it indispensable in rheumatology and infectious disease. As an antimalarial, HCQ interferes with lysosomal function in intraerythrocytic Plasmodium parasites — it is a weakly basic compound that concentrates in the acidic food vacuole of malaria parasites (the digestive organelle), raising vacuolar pH and inhibiting haemoglobin degradation and haem detoxification, causing toxic haem accumulation and parasite death. As an immunomodulator, HCQ interferes with multiple pathological immune mechanisms: (1) Lysosomal processing inhibition — by raising lysosomal pH, HCQ impairs antigen presentation to autoreactive T-cells (reduced MHC class II antigen presentation); (2) Toll-like receptor (TLR) inhibition — HCQ blocks endosomal TLR7 and TLR9 activation by nucleic acid ligands, reducing interferon-alpha production in SLE; (3) Autophagy modulation — disrupting autophagosome-lysosome fusion; (4) Anti-platelet and lipid-modifying effects — HCQ reduces platelet aggregation, improves lipid profiles, and has antithrombotic properties relevant in antiphospholipid syndrome. In rheumatoid arthritis, HCQ is a first-line DMARD in combination with methotrexate and sulfasalazine (triple therapy).

Clinical Indications

Hqtor 400mg Tablet (hydroxychloroquine) is clinically indicated for rheumatoid arthritis (DMARD — monotherapy or combination with methotrexate/sulfasalazine), systemic lupus erythematosus (SLE — reduces flares, organ damage, and mortality), lupus nephritis (adjunct), primary Sjögren’s syndrome, discoid lupus erythematosus, and malaria prophylaxis/treatment. All pharmacotherapy for the conditions in this batch should be initiated under qualified medical supervision — self-diagnosis and self-treatment of neurological, psychiatric, and infectious conditions can be dangerous and may delay appropriate care.

Dosage and Administration

RA/SLE: 400mg once or twice daily with food. Dose based on ideal body weight — maximum 5mg/kg/day actual body weight (critical for reducing retinal toxicity risk). For SLE: 200–400mg/day long-term. For RA: 200–400mg/day as part of combination DMARD therapy. Take with food to reduce GI effects.

Contraindications

Hypersensitivity to hydroxychloroquine or chloroquine. Pre-existing maculopathy or significant visual field defect (retinal toxicity risk). G6PD deficiency (relative — may cause haemolytic anaemia at higher doses). Porphyria. QTc prolongation (caution with concurrent QTc-prolonging drugs).

Drug Interactions

QTc-prolonging drugs: additive QTc risk — particularly azithromycin (a combination used during COVID-19 investigations showed increased arrhythmia risk). Digoxin: HCQ increases digoxin levels — monitor. Antidiabetics: HCQ has modest hypoglycaemic effect — may enhance antidiabetic drug effect. Methotrexate: safe and commonly combined in RA triple therapy. Ciclosporin: increased ciclosporin levels. Tamoxifen: increased retinal toxicity risk — avoid combination.

A comprehensive medication review before starting any new drug is essential. Neurological and psychiatric medications have numerous clinically important interactions — inform all healthcare providers of your complete medication list.

Adverse Effects

GI effects (nausea, vomiting, diarrhoea — reduced by taking with food). Skin reactions (pigmentation, rash, pruritus). Retinal toxicity (the most important long-term adverse effect — macular damage causing irreversible vision loss; risk increases after >5 years use or cumulative dose >1000g). QTc prolongation. Rare: hepatotoxicity, blood dyscrasias, neuromyopathy.

Special Population Considerations

RETINAL SCREENING IS MANDATORY: Annual ophthalmological assessment (visual field testing and OCT retinal imaging) is required after 5 years of HCQ therapy (or sooner if risk factors present — renal impairment, tamoxifen use, high-dose therapy). Early detection of HCQ maculopathy allows drug cessation before vision loss becomes severe. Risk is substantially lower when the dose remains below 5mg/kg/day ideal body weight — prescribers must calculate weight-based maximum dose. HCQS/Hydroquin 200mg tablets are widely used in India and are among the most commonly prescribed DMARDs for RA and SLE.

Storage

Store Hqtor 400mg at room temperature (15–25°C) away from direct sunlight, moisture, and heat. Keep in original packaging out of reach of children and pets. Do not use beyond the expiry date.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next dose. Never double-dose. Do not stop antiepileptic medications abruptly without medical guidance.

Q: Why do I need annual eye tests while taking hydroxychloroquine?
A: Hydroxychloroquine can cause retinopathy — damage to the macula (the central part of the retina responsible for detailed vision). This damage occurs in approximately 7.5% of patients taking HCQ for more than 5 years. Unfortunately, once severe maculopathy develops it causes irreversible vision loss. Annual screening with specific retinal imaging (OCT) and visual field testing allows detection of early changes before vision is significantly affected. If caught early, stopping HCQ prevents progression. Never skip your annual eye review — it can save your vision.

Evidence Base and Clinical Guidelines

The active ingredient in Hqtor 400mg is supported by randomised controlled trial evidence and incorporated into major international clinical guidelines including those from the European Federation of Neurological Societies (EFNS), International Headache Society (IHS), American Academy of Neurology (AAN), WHO, MASCC, and relevant national specialist bodies. GMP-compliant manufacturing ensures consistent product quality, identity, and strength across all batches.

Disease Management and Lifestyle Context

Pharmacological therapy delivers best outcomes when integrated with appropriate lifestyle measures, patient education, and regular clinical review. For migraine: identifying and avoiding personal triggers (stress, sleep disruption, dietary factors), maintaining sleep regularity, and managing anxiety/depression significantly reduce attack frequency alongside preventive pharmacotherapy. For epilepsy: medication adherence, sleep regularity, alcohol avoidance, and seizure first-aid education for caregivers are essential components. For malaria: vector avoidance (bed nets, repellents, protective clothing), travel prophylaxis where indicated, and prompt treatment of fever in endemic areas are critical public health measures. For autoimmune conditions: joint protection strategies, physiotherapy, and monitoring for disease complications complement pharmacotherapy.

Patient Counselling Key Points

• Never stop antiepileptic drugs (AEDs) abruptly — abrupt AED withdrawal can precipitate status epilepticus, a life-threatening medical emergency. Any dose reduction or discontinuation requires gradual tapering under neurologist supervision over weeks to months.
• Driving restrictions: Patients with epilepsy must follow national regulations regarding driving — typically a seizure-free period of 6–12 months required. Medications causing sedation (amitriptyline, some antiemetics, antiepileptics) may impair driving ability — seek advice before driving.
• Pregnancy planning: Multiple drugs in this batch have teratogenic risks (divalproex — highest risk; carbamazepine; topiramate; amitriptyline). Women of childbearing age should discuss contraception and pregnancy planning with their specialist before starting these medications.

Neurological and Psychiatric Disease Context

Migraine affects approximately 1 billion people worldwide — making it the second most disabling neurological condition globally (after stroke) by disability-adjusted life-years (DALYs). Despite its prevalence, migraine remains significantly under-diagnosed and undertreated. The burden of migraine extends far beyond the attack itself — between attacks, anticipatory anxiety, activity avoidance, and the impact on employment, relationships, and quality of life are substantial. Effective migraine management requires a comprehensive approach: accurate diagnosis, acute attack management with triptans or NSAIDs, identification and avoidance of personal triggers, and preventive pharmacotherapy when attacks occur ≥4 days/month or are particularly disabling.

Epilepsy affects approximately 50 million people globally — a lifelong condition requiring adherence to antiepileptic drugs (AEDs) that may be lifelong. Modern antiepileptic pharmacology has expanded dramatically over the past three decades — from phenobarbitone, phenytoin, and carbamazepine, to the introduction of valproate, lamotrigine, topiramate, oxcarbazepine, levetiracetam, and multiple newer agents. The goal of epilepsy management is complete seizure freedom with minimum drug toxicity — 70% of patients achieve seizure freedom on AEDs, allowing many to eventually withdraw medication after prolonged seizure-free periods.

Malaria remains a major global public health emergency — the WHO estimates 247 million malaria cases and 619,000 malaria deaths annually, predominantly in sub-Saharan Africa. The discovery that artemisinin-based combination therapies (ACTs) dramatically outperform previous treatments has been transformative — ACT implementation has saved millions of lives. However, emerging partial artemisinin resistance in Southeast Asia represents an increasing threat to global malaria control.

Nausea and Vomiting Management Context

Nausea and vomiting are among the most disabling symptoms in oncology patients — impacting quality of life, nutritional status, hydration, and treatment adherence. Despite advances in antiemetic pharmacology (5-HT3 antagonists, NK1 antagonists, dexamethasone), chemotherapy-induced nausea and vomiting (CINV) remains incompletely controlled — particularly delayed CINV (>24 hours post-chemotherapy). The triple antiemetic regimen (5-HT3 + NK1 + dexamethasone) represents the current gold standard for highly emetogenic chemotherapy, achieving complete emesis control in 70–80% of patients during the acute phase and 60–70% during the delayed phase.

Evidence Base and Quality Standards

The active ingredients in this product range have been evaluated in landmark randomised controlled trials and systematic reviews, supported by major international guidelines including those from the International Headache Society (IHS), European Federation of Neurological Societies (EFNS), WHO, MASCC/ASCO antiemetic guidelines, and national specialist bodies. GMP-compliant manufacturing ensures consistent product quality, identity, and safety across all batches.

Patient Safety and Medication Adherence

Adherence to neurological medications — antiepileptics, migraine preventives, antimalarials, and antidepressants — is critical for optimal outcomes. For antiepileptic drugs, even a single missed dose can trigger breakthrough seizures with potentially catastrophic consequences (status epilepticus, injury, drowning). For migraine preventives (valproate, topiramate, flunarizine, amitriptyline), consistent daily dosing for at least 3 months is required before efficacy can be assessed — premature discontinuation due to early side effects or perceived lack of benefit is a major cause of preventive therapy failure. For antimalarial treatment, completing the full prescribed course is essential — incomplete treatment leads to treatment failure, recrudescence, and contributes to drug resistance development.

Polypharmacy risks are particularly significant in neurological and psychiatric patients — drug-drug interactions in this population can cause dangerous outcomes: carbamazepine reducing oral contraceptive efficacy (unintended pregnancy); valproate dramatically increasing lamotrigine levels (toxicity); MAO inhibitor interactions with triptans, SSRIs, or amitriptyline (serotonin syndrome); QTc prolongation with combinations of thioridazine, antifungals, or fluoroquinolone antibiotics. A comprehensive medication review before any new prescription in these patients is not optional — it is a clinical safety imperative.

Special Populations Requiring Additional Attention

Elderly patients receiving antiemetics, antiepileptics, and psychiatric medications face heightened risks: metoclopramide extrapyramidal reactions are more common and severe in the elderly; amitriptyline’s anticholinergic effects (confusion, urinary retention, falls) place elderly patients at unacceptable risk; benzodiazepine-amitriptyline combinations can cause respiratory depression and falls. For women of childbearing age: valproate/divalproex, topiramate, and carbamazepine all carry teratogenicity risks requiring counselling and contraception planning before and during therapy. Pregnancy requires specialist review of all neurological, psychiatric, and antimalarial medications — the benefit-risk calculus changes dramatically when foetal wellbeing is considered alongside maternal health management.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed pharmacological and clinical literature, and established guidelines. It does not replace professional medical advice, diagnosis, or treatment from a qualified neurologist, psychiatrist, infectious disease specialist, rheumatologist, or pharmacist. Self-diagnosis and self-treatment of neurological, psychiatric, infectious, and autoimmune conditions can be dangerous and life-threatening. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.